TEAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TEAM is not a good buy right now. The stock is in a clear downtrend (bearish moving averages and worsening MACD), headline risk is elevated (securities-fraud investigation headlines), and earnings are close (Feb 5). While it’s near support and somewhat oversold (which can spark a bounce), there is no Intellectia buy signal to prioritize and the technical tape is still weak—so an impatient buyer is more likely to get a worse fill than a quick win.
Trend/structure: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend. Momentum: MACD histogram is -0.73 and expanding negatively, signaling downside momentum is still increasing rather than stabilizing. RSI: RSI_6 at ~28.25 is near oversold conditions (often associated with short-term bounce potential), but oversold alone is not a reversal signal. Key levels: Price ~117.95 is sitting right on S1 support (117.585). A clean break below increases risk toward S2 (111.527). Overhead resistance is heavy: pivot 127.391 then R1 137.197. Pattern-based short-term odds: Similar-pattern analysis suggests modest upside bias beyond 1 day (next week +1.61%, next month +7.58%), but this conflicts with currently deteriorating momentum.
Intellectia Proprietary Trading Signals
with near-oversold RSI, which can produce a quick mean-reversion pop.
Downtrend still intact: Bearish MA stack and expanding negative MACD indicate sellers remain in control.
Event/headline risk: Pomerantz LLP investigation headlines (securities fraud inquiry) can keep pressure on the stock and amplify volatility.
Analyst target cuts and AI disruption fears: Multiple firms cited multiple compression and AI-disruption concerns; this keeps valuation and narrative under pressure.
Earnings proximity: With earnings on 2026-02-05, the stock can move sharply; without a clear technical reversal signal, odds are unfavorable for an impatient entry.
Recent sharp selloff: The stock recently dropped ~7.7% on downgrade/target-cut headlines, suggesting fragile sentiment.
Latest quarter: 2026/Q1. Growth: Revenue rose to $1.432B (+20.61% YoY), showing strong top-line expansion. Profitability: Net income fell to -$51.87M (down 58.09% YoY) and EPS to -0.20 (down 58.33% YoY), indicating profitability is deteriorating despite growth. Margins: Gross margin improved to 82% (+0.39% YoY), reflecting strong unit economics, but operating/earnings leverage is not translating to bottom-line improvement in this snapshot. Overall: Healthy revenue growth and high gross margin, but worsening net losses reduce near-term fundamental support for a quick buy-the-dip trade.
Recent trend: Broad wave of price target reductions in January 2026 (UBS 185→145 Neutral; Baird 230→170 Outperform; BofA 200→170 Neutral; TD Cowen 205→175 Hold; Citi 240→210 Buy; Mizuho 245→225 Outperform; Piper 300→280 Overweight). Despite cuts, several bullish firms maintain positive ratings and high targets (e.g., Morgan Stanley Overweight $320; Oppenheimer Outperform $275). Wall Street pros: (1) Shares appear discounted after a large drawdown; (2) cloud momentum and enterprise engagement may stay resilient; (3) long-term growth drivers (seat growth, pricing, migrations, cross-sell, AI consumption) remain intact. Wall Street cons: (1) Data center-to-cloud migration creates uncertainty and could reset growth expectations; (2) AI disruption fears and multiple compression continue to weigh on SaaS; (3) near-term sentiment is weak given repeated target cuts. Influential/congress trading: No recent congress trading data available; hedge funds and insiders show neutral activity (no significant recent trend).
